Risen (Suzhou) Pharma Tech Co., Ltd.
Risen (Suzhou) Pharma Tech Co., Ltd.
Explore linked clinical trials.3 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| To Evaluate the Safety and Efficacy of RP902 Tablets | Cognition Disorders, Cognitive Dysfunction, cognitive disorder, psychiatric disorder | Recruiting | Phase 2 | 2026-10-01 | NCT07579884 | |
| A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer. | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 3 | 2025-12-30 | NCT07207070 | |
| A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors | Advanced Solid Tumors | Recruiting | Phase 1 / Phase 2 | 2025-07-25 | NCT06208410 |